Literature DB >> 28145671

Evaluation of Jaundice in Adults.

Matthew V Fargo1, Scott P Grogan2, Aaron Saguil3.   

Abstract

Jaundice in adults can be an indicator of significant underlying disease. It is caused by elevated serum bilirubin levels in the unconjugated or conjugated form. The evaluation of jaundice relies on the history and physical examination. The initial laboratory evaluation should include fractionated bilirubin, a complete blood count, alanine transaminase, aspartate transaminase, alkaline phosphatase, ?-glutamyltransferase, prothrombin time and/or international normalized ratio, albumin, and protein. Imaging with ultrasonography or computed tomography can differentiate between extrahepatic obstructive and intrahepatic parenchymal disorders. Ultrasonography is the least invasive and least expensive imaging method. A more extensive evaluation may include additional cancer screening, biliary imaging, autoimmune antibody assays, and liver biopsy. Unconjugated hyperbilirubinemia occurs with increased bilirubin production caused by red blood cell destruction, such as hemolytic disorders, and disorders of impaired bilirubin conjugation, such as Gilbert syndrome. Conjugated hyperbilirubinemia occurs in disorders of hepatocellular damage, such as viral and alcoholic hepatitis, and cholestatic disorders, such as choledocholithiasis and neoplastic obstruction of the biliary tree.

Entities:  

Mesh:

Year:  2017        PMID: 28145671

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  8 in total

1.  Comparative Study of the Results of Operations in Patients with Tumor and Non-Tumor Obstructive Jaundice Who Received and Did Not Receive Antioxidant Therapy for the Correction of Endotoxemia, Glycolysis, and Oxidative Stress.

Authors:  Victor Stupin; Igor Abramov; Teymur Gahramanov; Alexey Kovalenko; Natalia Manturova; Petr Litvitskiy; Zalim Balkizov; Ekaterina Silina
Journal:  Antioxidants (Basel)       Date:  2022-06-20

2.  Etiology, Clinical Presentations, and Short-Term Treatment Outcomes of Extrahepatic Obstructive Jaundice in South-Western Uganda.

Authors:  Charles Newton Odongo; Carlos Cabrera Dreque; David Mutiibwa; Felix Bongomin; Felix Oyania; Mvuyo Maqhawe Sikhondze; Moses Acan; Raymond Atwine; Fred Kirya; Martin Situma
Journal:  Clin Exp Gastroenterol       Date:  2022-06-11

3.  Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma.

Authors:  Chun-Wei Huang; Tsung-Han Wu; Heng-Yuan Hsu; Kuang-Tse Pan; Chao-Wei Lee; Sio-Wai Chong; Song-Fong Huang; Sey-En Lin; Ming-Chin Yu; Shen-Ming Chen
Journal:  J Pers Med       Date:  2022-03-23

4.  Educational Case: Pancreatic Adenocarcinoma: Clinical Presentation, Pathogenesis, Diagnostic, and Therapeutic Modalities.

Authors:  Katya Dombrowski; Saeed Asiry; Agnes Colanta; Samer N Khader
Journal:  Acad Pathol       Date:  2020-09-10

5.  Escitalopram-induced hepatitis: A case report.

Authors:  Guillaume Wabont; Laurie Ferret; Nicolas Houdre; Antoine Lepied; Johana Bene; Etienne Cousein
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

6.  A breakthrough trial of an artificial liver without systemic heparinization in hyperbilirubinemia beagle models.

Authors:  Yilin Wang; Shanshan Wang; Xueqin He; Yupei Li; Tao Xu; Lin Xu; Bo Yang; Xinnian Fan; Weifeng Zhao; Changsheng Zhao
Journal:  Bioact Mater       Date:  2022-07-06

7.  Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis.

Authors:  Albert Parés; Mitchell Shiffman; Victor Vargas; Pietro Invernizzi; Elizabeth S Malecha; Alexander Liberman; Leigh MacConell; Gideon Hirschfield
Journal:  Liver Int       Date:  2020-03-24       Impact factor: 5.828

8.  Serum and Hepatic Autofluorescence as a Real-Time Diagnostic Tool for Early Cholestasis Assessment.

Authors:  Anna C Croce; Giovanni Bottiroli; Laura G Di Pasqua; Clarissa Berardo; Veronica Siciliano; Vittoria Rizzo; Mariapia Vairetti; Andrea Ferrigno
Journal:  Int J Mol Sci       Date:  2018-09-05       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.